Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-95251 in acute myeloid leukemia and myelodysplastic syndromes
NCT05168202Phase 1Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2022
- Primary completion
- Jul 2024
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 1, open-label trial of anzurstobart in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Dose-Limiting Toxicities at 42 days, Treatment Emergent Adverse Events at 30 months and 4 more. Started Jan 2022; status: terminated.
02
Drugs
anzurstobart
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05168202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05168202.